Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Trial Profile

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Cerebral haemorrhage; Intracranial haemorrhages; Stroke
  • Focus Therapeutic Use
  • Acronyms AREST
  • Most Recent Events

    • 02 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 08 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top